{"id":16774,"date":"2020-07-20T06:12:47","date_gmt":"2020-07-20T06:12:47","guid":{"rendered":"https:\/\/genesis-biomed.com\/?p=16774"},"modified":"2026-11-09T13:25:20","modified_gmt":"2026-11-09T12:25:20","slug":"un-sector-en-buena-forma-pese-crisis-covid-19","status":"publish","type":"post","link":"https:\/\/genesis-biomed.com\/es\/un-sector-en-buena-forma-pese-crisis-covid-19\/","title":{"rendered":"Un sector en buena forma pese a la crisis de Covid-19"},"content":{"rendered":"

[vc_row css_animation=\u00bb\u00bb row_type=\u00bbrow\u00bb use_row_as_full_screen_section=\u00bbno\u00bb type=\u00bbfull_width\u00bb angled_section=\u00bbno\u00bb text_align=\u00bbleft\u00bb background_image_as_pattern=\u00bbwithout_pattern\u00bb][vc_column][vc_single_image image=\u00bb16814″ img_size=\u00bbfull\u00bb qode_css_animation=\u00bb\u00bb][vc_empty_space height=\u00bb60″][vc_column_text]<\/p>\n

ITEMAS last webinar showed the optimism of healthcare investors<\/strong><\/span><\/h3>\n

[\/vc_column_text][\/vc_column][\/vc_row][vc_row css_animation=\u00bb\u00bb row_type=\u00bbrow\u00bb use_row_as_full_screen_section=\u00bbno\u00bb type=\u00bbfull_width\u00bb angled_section=\u00bbno\u00bb text_align=\u00bbleft\u00bb background_image_as_pattern=\u00bbwithout_pattern\u00bb][vc_column width=\u00bb1\/2″][vc_empty_space][vc_column_text]ITEMAS<\/a><\/span> last\u00a0webinar on Investment in Covid-19 times (\u201cImpact of Covid-19 in private and corporative investment) reflected the investors optimism regarding future investments in the healthcare sector despite the economical crisis caused by the Covid-19 pandemic. Speakers included Clara Camp\u00e0s<\/strong>, Managing Partner and Co-founder at\u00a0ASABYS Partners<\/a>; Llu\u00eds Pareras<\/strong>, Founding partner at Invivo Capital<\/a>; Ion Arocena<\/strong>, General Manager at\u00a0ASEBIO<\/a><\/span> (Spanish Biotech Companies Association) and Josep Llu\u00eds Falc\u00f3<\/strong>, CEO and Co-founder at GENESIS Biomed<\/span><\/a> and investment vehicle\u00a0GENESIS Ventures<\/a><\/span>.<\/p>\n

The session was presented by Ester Garc\u00eda<\/strong> from Instituto de Investigaci\u00f3n Sanitaria Arag\u00f3n (IISA<\/a><\/span>) and moderated by\u00a0Diego Velasco<\/strong>, Innovation Manager at Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS<\/a><\/span>).[\/vc_column_text][vc_empty_space height=\u00bb15px\u00bb][vc_column_text]One of the main conclusions was that unlike the rest of the economy, the life sciences sector in Spain has not been as badly hit by the crisis caused by Covid-19. Most innovation projects are going ahead and a great number of investment rounds are being closed. In fact, 2020 might set a new record high in the number of investments<\/strong>, as pointed by the speakers. \u201cThere are 700 million euros available for investments in healthcare\u201d said Clara Camp\u00e0s, who said that Spanish startups \u201chave also the capacity to attract international investment\u201d. According to Ion Arocena, \u201cCovid-19 has revealed to investors the potential of the healthcare sector\u201d. Llu\u00eds Pareras explained that \u201cour sector is not affected by the external ups and down of the economy, what is important is the quality of the innovation projects\u201d. The fact that life sciences funds completed their fundraising during the period 2018-2019, just before the coronavirus crisis, \u201cguarantees that there will be investments in healthcare<\/strong>\u201d, said Josep Llu\u00eds Falc\u00f3.[\/vc_column_text][vc_empty_space height=\u00bb15px\u00bb][vc_column_text]Clinical trials suffered with the pandemic<\/strong><\/p>\n

The most important impact of Covid-19 in healthcare innovation was the interruption of clinical trials<\/strong> during the most critical stage of the crisis. ASEBIO is working on an study to analyse the impact of the pandemic in the biotech sector and the preliminary results show that it has been quite mild. \u201cIf the sector had not been so mature the consequences would have been worse\u201d said Arocena, who highlighted positive changes prompted by the crisis: \u201cregulatory agencies have shown flexibility and allowed the use of telemedicine and patient monitorisation\u201d. This enforced break has given companies time to focus on their business plan, planning their fundraising strategy and all other back-office tasks\u201d pointed Falc\u00f3. Pareras criticised that some companies have diverted their initial focus with the goal to apply to Covid-19 funding calls and he advised entrepreneurs to \u201ckeep the the focus and avoid changing the scope of their innovation\u201d. According to Camp\u00e0s, the fact that biotech sector has been \u201chistorically under-funded<\/strong>\u201d is the reason why companies are applying to these calls despite their innovation is hardly applicable to the Covid-19 crisis.[\/vc_column_text][vc_empty_space][\/vc_column][vc_column width=\u00bb1\/2″][vc_empty_space][vc_column_text]A good time to start a company<\/strong><\/p>\n

Despite the difficult moment, investors agreed that it is now a good time to start a company as there is a growing interest from private funds and new innovation funding calls from public entities. \u201cInvestors have realised that the biotech and healthcare sector is essential for a welfare society<\/strong>. This year there will be a new record high of investments\u201d, said Pareras. Falc\u00f3 explained that GENESIS Biomed has been active creating new companies: \u201cIn the last months we have founded two companies and we will create four new ones until the end of the year\u201d. The consultancy firm is assisting Madrid\u2019s Regional Health Department in the creation of four spinoffs from hospitals in the capital city. The region is seeing a new wave of entrepreneurship with a great number of new research projects turning into new companies.<\/p>\n

The speakers highlighted that most investment funds are based in Catalonia<\/strong> but that are not geographically biased when investing in start-ups, what counts is the quality of the innovation. However, as pointed by Clara Camp\u00e0s, \u201cit is important to make sure that the new company is \u00a0legally constituted in a city able to attract international talent and investors\u201d. Ion Arocena pointed that Catalonia \u201cis a role model<\/strong> as it has been working for many years to stimulate research and innovation, promoting the public-private collaboration\u201d.[\/vc_column_text][vc_empty_space height=\u00bb15px\u00bb][vc_column_text]He also highlighted the \u201cimportant driving force\u201d<\/strong> that is ITEMAS to promote innovation in the Spanish biotech sector. The platform has a fundamental role supporting innovation in healthcare institutions across Spain and promoting entrepreneurship. Promoted by<\/span> Instituto de Salud Carlos III<\/a><\/span>, it has 184 members including healthcare centres, private companies and public organisations. Their main goal is to promote R&D projects that improve healthcare and benefit society.<\/p>\n

GENESIS Biomed thanks ITEMAS the opportunity to sponsor the webinars series on Investment in Covid-19 times, which have been a participation success with over 500 professionals connected to the four webinars celebrated in June and July.[\/vc_column_text][vc_empty_space height=\u00bb15px\u00bb][vc_column_text]The\u00a0documents<\/a><\/span><\/strong>\u00a0related to the webinars have been published in ITEMAS website.<\/p>\n

You can read the recap of the webinars and see the visual thinking illustrations of artist Fernando Viejo-Fluiters in GENESIS Biomed website:<\/p>\n

ITEMAS is in favour of the creation of a fund or investment instrument for early stage projects<\/a><\/span><\/h5>\n
How to raise private funding: evaluation of an innovation project<\/a><\/span><\/h5>\n
A solid science and the right patent: keys to raise private funding<\/a><\/span><\/h5>\n

[\/vc_column_text][vc_empty_space][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Los inversores, optimistas pese a la pandemia. <\/p>\n","protected":false},"author":2,"featured_media":16814,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[373,232,273,255,212,228,281,5],"tags":[270,271,272,279],"class_list":["post-16774","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog-es","category-genesis-biomed","category-genesis-biomed-es","category-genesis-ventures","category-investment-projects","category-medtech","category-medtech-es","category-news","tag-innovacion-es","tag-inversion-es","tag-itemas-es","tag-itemas-es-2"],"_links":{"self":[{"href":"https:\/\/genesis-biomed.com\/es\/wp-json\/wp\/v2\/posts\/16774","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/genesis-biomed.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/genesis-biomed.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/genesis-biomed.com\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/genesis-biomed.com\/es\/wp-json\/wp\/v2\/comments?post=16774"}],"version-history":[{"count":13,"href":"https:\/\/genesis-biomed.com\/es\/wp-json\/wp\/v2\/posts\/16774\/revisions"}],"predecessor-version":[{"id":29412,"href":"https:\/\/genesis-biomed.com\/es\/wp-json\/wp\/v2\/posts\/16774\/revisions\/29412"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/genesis-biomed.com\/es\/wp-json\/wp\/v2\/media\/16814"}],"wp:attachment":[{"href":"https:\/\/genesis-biomed.com\/es\/wp-json\/wp\/v2\/media?parent=16774"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/genesis-biomed.com\/es\/wp-json\/wp\/v2\/categories?post=16774"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/genesis-biomed.com\/es\/wp-json\/wp\/v2\/tags?post=16774"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}